March wasn’t the busiest month for big pharma shakeups, especially compared to the start of the year, but there was plenty of hustle and bustle at smaller pharma and biotech firms.
Digital may be upending every aspect of the pharma industry, but many would assume that engagement activities like advisory boards, working groups and medical education will remain a bastio
